American Association for Cancer Research
10780432ccr193922-sup-233272_5_supp_6187036_q7t10b.docx (15.38 kB)

Tables S2-1 and S2-2 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Download (15.38 kB)
journal contribution
posted on 2023-03-31, 22:06 authored by Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, Jun Guo

Clinical efficacy and survival evaluated by independent review committee (IRC) and investigator per RECIST v1.1 in melanoma subgroups. And Top 20% TMB value in each subtype as cut-off for efficacy analysis.


National Major Science & Technology

National Natural Science Foundation of China

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support

Beijing Municipal Science and Technology Commission



In contrast to the predominant chronic UV exposure–induced cutaneous melanoma in Caucasians, acral and mucosal comprise the majority of melanomas in Asia and respond less effectively to established treatments. The clinical application of PD-1 blockade is yet to be explored in metastatic melanoma in China. This phase II study was to evaluate safety and efficacy of toripalimab in advanced Chinese patients with melanoma who had failed in systemic treatments. Toripalimab was given at 3 mg/kg i.v. once every 2 weeks until disease progression or unacceptable toxicity. The primary objective was safety and objective response rate. 128 Patients with melanoma were enrolled, including 50 acral and 22 mucosal. As of August 15, 2019, 23 months after the last enrollment, 116 (90.6%) experienced treatment-related adverse events. ≥Grade 3 TRAEs occurred in 25 (19.5%) patients. Among 127 patients assessed, 1 complete response, 21 partial response, and 51 stable disease were observed for objective response rate of 17.3% and disease control rate of 57.5%. Median duration of response was not reached. Median progression-free survival was 3.6 months [95% confidence interval (CI) 2.7–5.3] and median overall survival was 22.2 months (95% CI, 15.3–NE). Patients with positive PD-L1 staining in tumor biopsies had significant better ORR (38.5% vs. 11.9%, P = 0.0065), PFS (7.7 months vs. 2.7 months, P = 0.013), and OS (not reached vs. 14.4 months, P = 0.0005) than PD-L1–negative patients. This is the largest prospective anti-PD-1 clinical study in advanced melanoma with predominantly acral and mucosal subtypes. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma refractory to standard therapy.See related commentary by Shoushtari et al., p. 4171

Usage metrics

    Clinical Cancer Research



    Ref. manager